奎硫平与氟哌啶醇治疗精神分裂症的临床分析

A clinical analysis between quetiapine and haloperidol in the treatment of schizophrenia

目的:探讨奎硫平治疗精神分裂症的临床疗效及安全性,并与氟哌啶醇进行比较。方法:72例符合中国精神障碍分类与诊断标准的精神分裂症患者被随机分为两组,分别给予奎硫平和氟哌啶醇治疗8周,以阳性和阴性症状量表(PANSS)进行疗效评定,以不良反应量表(TESS)评定不良反应。结果:8周末奎硫平组有效率94.5%,氟哌啶醇组为91.7%,两组间的差异无显著性(P>0.05)。奎硫平组认知症状评分显著低于氟哌啶醇组(P<0.05);奎硫平组总的不良反应发生率为38.89%,氟哌啶醇组为75%,差异有显著性(P<0.01)。结论:奎硫平治疗精神分裂症的总体疗效与氟哌啶醇相当,认知症状改善优于氟哌啶醇,不良反应发生率明显低于氟哌啶醇。

Objective：To compare the efficacy and safety of quetiapine and haloperidol in the treatment of schizophrenia. Methods ：72 patients with schizophrenia by CCMD -3 were randomly allocated to two groups treated with quetiapine or haloperidol for 8 weeks. The Positive and Negative Syndrome Scale （PANSS） and Treatment Emergent Side effect Scale （TESS） were used to evaluate efficacy and adverse effect respectively. Results： The efficacy rates of quetiapine was 94.5%, and the significant efficacy rates was 91.7% after 8 weeks, without any significant difference between two groups （P 〉0.05 ）. However, the incidence rate of adverse effect is 38.89% and 75.00% respectively, significantly lower in quetiapine group （P 〈0.01 ）. Scores of cognitive function were significantly lower in quetiapine group than those in haloperdol group （P 〈 0.05 ）. Conclusions： Quetiapine has a similar total efficacy but fewer side effects compared with haloperidol, quetiapine may have a better effect on cognitive function than that of haloperidol.